These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 16707008)

  • 1. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma.
    Koch CA; Brouwers FM; Vortmeyer AO; Tannapfel A; Libutti SK; Zhuang Z; Pacak K; Neumann HP; Paschke R
    BMC Cancer; 2006 May; 6():131. PubMed ID: 16707008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma.
    Koch CA; Huang SC; Zhuang Z; Stolle C; Azumi N; Chrousos GP; Vortmeyer AO; Pacak K
    Oncogene; 2002 Jan; 21(3):479-82. PubMed ID: 11821960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma.
    Koch CA; Huang SC; Moley JF; Azumi N; Chrousos GP; Gagel RF; Zhuang Z; Pacak K; Vortmeyer AO
    Oncogene; 2001 Nov; 20(53):7809-11. PubMed ID: 11753660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetics of medullary thyroid cancer: An overview.
    Accardo G; Conzo G; Esposito D; Gambardella C; Mazzella M; Castaldo F; Di Donna C; Polistena A; Avenia N; Colantuoni V; Giugliano D; Pasquali D
    Int J Surg; 2017 May; 41 Suppl 1():S2-S6. PubMed ID: 28506408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II.
    Neumann HP; Eng C; Mulligan LM; Glavac D; Zäuner I; Ponder BA; Crossey PA; Maher ER; Brauch H
    JAMA; 1995 Oct; 274(14):1149-51. PubMed ID: 7563486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
    Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
    Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
    D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
    J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.
    Marsh DJ; Andrew SD; Eng C; Learoyd DL; Capes AG; Pojer R; Richardson AL; Houghton C; Mulligan LM; Ponder BA; Robinson BG
    Cancer Res; 1996 Mar; 56(6):1241-3. PubMed ID: 8640806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coincidence of multiple endocrine neoplasia type 2A with acromegaly.
    Saito T; Miura D; Taguchi M; Takeshita A; Miyakawa M; Takeuchi Y
    Am J Med Sci; 2010 Oct; 340(4):329-31. PubMed ID: 20739875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
    Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
    Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient affected by neurofibromatosis type 1 and thyroid C-cell hyperplasia harboring pathogenic germ-line mutations in both NF1 and RET genes.
    Ercolino T; Lai R; Giachè V; Melchionda S; Carella M; Delitala A; Mannelli M; Fanciulli G
    Gene; 2014 Feb; 536(2):332-5. PubMed ID: 24361808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modifying impact of
    Kaczmarek-Ryś M; Ziemnicka K; Pławski A; Budny B; Michalak M; Hryhorowicz S; Hoppe-Gołębiewska J; Boruń P; Gołąb M; Czetwertyńska M; Sromek M; Szalata M; Ruchała M; Słomski R
    Endocr Relat Cancer; 2018 Apr; 25(4):421-436. PubMed ID: 29386230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
    Moore SW; Appfelstaedt J; Zaahl MG
    J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Krampitz GW; Norton JA
    Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma.
    Bockhorn M; Frilling A; Kalinin V; Schröder S; Broelsch CE
    Langenbecks Arch Surg; 1999 Feb; 384(1):60-4. PubMed ID: 10367632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes.
    Zupan A; Glavač D
    Exp Mol Pathol; 2015 Dec; 99(3):416-25. PubMed ID: 26321248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
    Menon MM; Simha MR
    Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.